<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02065882</url>
  </required_header>
  <id_info>
    <org_study_id>Biotest 984</org_study_id>
    <secondary_id>2011-004154-25</secondary_id>
    <nct_id>NCT02065882</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency</brief_title>
  <official_title>A Prospective, Open-label, Phase I/III Study Investigating Pharmacokinetic Properties of BT524 and Efficacy and Safety of BT524 in the Treatment and Prophylaxis of Bleeding in Patients With Congenital Fibrinogen Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotest</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>SYNLAB Analytics &amp; Services Germany GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Phoenix Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Accovion GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biotest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate pharmacokinetics, efficacy and safety of BT524 in&#xD;
      patients with congenital fibrinogen deficiency.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study is designed as a prospective, open-label, multicentre, phase I/III study&#xD;
      investigating the 14 day single-dose pharmacokinetic properties, efficacy and safety of BT524&#xD;
      following intravenous administration in the treatment or prophylaxis of bleeding in patients&#xD;
      with congenital afibrinogenemia or severe congenital hypofibrinogenemia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Terminal Elimination Half-life (t1/2) for fibrinogen antigen,</measure>
    <time_frame>Prior to the initial dose on day 1, at the end of the infusion and 0.5, 1, 2, 4, 8 hours post dose, 24, 48,96, 168, 240h and 336 hours post-dose</time_frame>
    <description>The primary objective of this study is to investigate the 14 day single-dose pharmacokinetics of BT524 following intravenous (IV) infusion in patients with congenital afibrinogenemia or severe congenital hypofibrinogenemia (part I).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-life (t1/2) for fibrinogen activity</measure>
    <time_frame>Prior to the initial dose on day 1, at the end of the infusion and 0.5, 1, 2, 4, 8 hours post dose, 24, 48,96, 168, 240 and 336 hours post-dose</time_frame>
    <description>Secondary objectives are to investigate the 14 day single-dose pharmacodynamics of BT524, and the surrogate efficacy and safety of BT524 in part I of the study. In addition, the hemostatic efficacy, surrogate efficacy, and safety of single and/or repetitive administrations for on-demand prophylaxis (ODP) and/or on-demand treatment (ODT) of bleeding events will be investigated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Congenital Afibrinogenemia</condition>
  <condition>Congenital Hypofibrinogenemia</condition>
  <arm_group>
    <arm_group_label>BT524</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous infusion of a fixed dose of 70 mg BT524 per kilogram body weight (BW)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BT524 (fibrinogen concentrate from human plasma)</intervention_name>
    <description>single intravenous infusion</description>
    <arm_group_label>BT524</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Known congenital afibrinogenemia or severe congenital hypofibrinogenemia&#xD;
&#xD;
          -  Plasma fibrinogen activity ≤ 0.5 g/l and antigen ≤ 0.5 g/l&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Age 0 to 75 years, with the first ten patients will be 18 years or&#xD;
&#xD;
          -  Presumed to be compliant with the study procedures and to terminate the study as&#xD;
             scheduled&#xD;
&#xD;
          -  Willing and able to be hospitalized for 3 days for the pharmacokinetic assessment (if&#xD;
             applicable)&#xD;
&#xD;
          -  Willing and able to be hospitalized - if required - in case of interventions (e.g.,&#xD;
             surgical procedures, major bleeds)&#xD;
&#xD;
          -  Written informed consent by the patient, his/her parents or by the patient's legal /&#xD;
             authorized representative as applicable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known congenital dysfibrinogenemia&#xD;
&#xD;
          -  Known bleeding disorder other than congenital fibrinogen deficiency&#xD;
&#xD;
          -  History of esophageal variceal bleeding&#xD;
&#xD;
          -  Known presence or history of venous/arterial thrombosis or thromboembolic event in the&#xD;
             preceding 6 months&#xD;
&#xD;
          -  Known presence or history of fibrinogen inhibitory antibodies&#xD;
&#xD;
          -  Known presence or history of hypersensitivity to human fibrinogen or human plasma&#xD;
             proteins e.g., immunoglobulins, vaccines or hypersensitivity to any of the excipients&#xD;
&#xD;
          -  Known positive serology for HIV-1 and HIV-2&#xD;
&#xD;
          -  Clinically relevant biochemical or hematological findings (except due to underlying&#xD;
             disease or emergency bleeding) outside the normal range (at the investigator's&#xD;
             discretion)&#xD;
&#xD;
          -  Clinically relevant pathological findings in physical examination including&#xD;
             electrocardiogram (ECG)&#xD;
&#xD;
          -  Treatment with any fibrinogen concentrate and/or fibrinogen-containing product within&#xD;
             2 weeks prior to infusion of BT524&#xD;
&#xD;
          -  Concomitant medication interacting relevantly with the coagulation system (e.g., low&#xD;
             molecular weight heparin, unfractioned heparin, factor Xa inhibitors, factor IIa&#xD;
             inhibitors or PY12 inhibitors) within 2 weeks prior to infusion of BT524&#xD;
&#xD;
          -  Recent vaccination (within 3 weeks prior to infusion)&#xD;
&#xD;
          -  Body weight (BW) below 22 kg for patients ≥ 6 years; BW below the 5th percentile of&#xD;
             the normal range for children &lt; 6 years (refers to local standard)&#xD;
&#xD;
          -  End stage disease&#xD;
&#xD;
          -  Abuse of drugs&#xD;
&#xD;
          -  Unable to understand and follow the study requirements&#xD;
&#xD;
          -  Participation in another interventional clinical study within 30 days before entering&#xD;
             the study or during the study&#xD;
&#xD;
          -  Pregnant/ nursing woman, or woman of childbearing potential not using reliable/&#xD;
             effective contraceptive method(s) during the study and at least one month after the&#xD;
             last administration of study drug (e.g., oral/ injectable/ implantable/ insertable/&#xD;
             topical hormonal contraceptives, intrauterine devices, female sterilization, partner's&#xD;
             vasectomy or condoms)&#xD;
&#xD;
          -  Any other condition that, to the investigator's judgment, could have an impact on&#xD;
             patient's safety or the study results&#xD;
&#xD;
          -  Elective surgery during the 14 day PK blood sampling period&#xD;
&#xD;
          -  Acute infection&#xD;
&#xD;
          -  Clinically relevant increase or decrease in body temperature&#xD;
&#xD;
          -  Actively bleeding or anticipated bleeding (including female menorrhea) at the time&#xD;
             point of or within 7 days prior to infusion of BT524&#xD;
&#xD;
          -  Surgery within 7 days prior to infusion of BT524&#xD;
&#xD;
          -  Immobilization within 7 days prior to infusion of BT524&#xD;
&#xD;
          -  Intake of alcohol or significantly increased intake of caffeine containing products&#xD;
             within 24 hours prior to infusion of BT524&#xD;
&#xD;
          -  Blood donation or comparable blood loss within 60 days prior to infusion of BT524&#xD;
&#xD;
          -  Excessive physical exercise (extreme sports activities, sauna) within 72 hours prior&#xD;
             to infusion of BT524&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Djambas Khayat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôtel Dieu de France, Dept. of Pediatrics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudia Schulte</last_name>
    <phone>+49 6103 801</phone>
    <phone_ext>4941</phone_ext>
    <email>claudia.schulte@biotest.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joachim Schütze, PhD</last_name>
    <phone>+49 6103 801</phone>
    <phone_ext>5127</phone_ext>
    <email>joachim.schuetze@biotest.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site 11</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Site 07</name>
      <address>
        <city>Gießen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 04</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site 03</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site 05</name>
      <address>
        <city>Padua</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site 06</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site 01</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 02</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site12</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Egypt</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Lebanon</country>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>February 3, 2014</study_first_submitted>
  <study_first_submitted_qc>February 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2014</study_first_posted>
  <last_update_submitted>July 24, 2019</last_update_submitted>
  <last_update_submitted_qc>July 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fibrinogen, bleeding,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Afibrinogenemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

